Read More Pharma Industry News SGX945 demonstrates lasting oral ulcer reduction in Phase 2 Behçet’s disease trial Find out how SGX945 achieved durable oral ulcer reduction in a phase 2 Behçet’s disease trial published in Rheumatology (Oxford). bySoujanya RaviDecember 18, 2025